With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.116131-44-3,3-(Bromomethyl)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.
Step 1: DMPU (225ml), FeCl3(0.75g) and CuCl (0.3g) are added to 3-bromomethyltetrahydropyran (24.75g, 0.138mol), and then Et2Zn (106.8ml) is slowly dropped at 40?45 C for 45 minutes to obtain a zinc-reagent. THF (810 ml) and PdCl2(dppf) (5.09 g) are added to 4-chloro-2-(4-chlorophenyl) – thieno[2,3-d]pyridazinyl-7-ethyl formate (30g), and then addition of the zinc-reagent to the THF solution and reacted at 45C for 4 hours. The above mixture is poured into a saturated brine, filtrated after stirring for 15 minutes and placed for layer separation. The aqueous phase is extracted with THF (500 ml, 2 times). The organic phase is combined together, washed with saturated brine (500ml, 3 times) and dried with anhydrous Na2SO4 and evaporated under reduced pressure to remove solvent to obtain 4-(3-tetrahydropyranmethyl)-2-(4-chlorophenyl)-thieno[2,3-d]pyridazinyl-7-ethyl formate (25 g). MS (ESI): 417(M+1), 116131-44-3
116131-44-3 3-(Bromomethyl)tetrahydro-2H-pyran 22617257, aTetrahydropyrans compound, is more and more widely used in various fields.
Reference£º
Patent; Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory; EP2241569; (2010); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics